Review: taking Novolog and Levemir together


Summary

Drug interactions are reported among people who take Novolog and Levemir together. This review analyzes the effectiveness and drug interactions between Novolog and Levemir. It is created by eHealthMe based on reports of 3,097 people who take the same drugs from FDA and social media, and is updated regularly.

You are not alone

Join a support group for people who take Novolog and Levemir >>>

Personalized health information

On eHealthMe you can find out what patients like me (same gender, age) reported their drugs and conditions on FDA and social media since 1977. Our tools are free and anonymous. 86 million people have used us. 300+ peer-reviewed medical journals have referenced our original studies. Start now >>>


Novolog

Novolog has active ingredients of insulin aspart recombinant. It is often used in diabetes. (latest outcomes from Novolog 13,768 users)

Levemir

Levemir has active ingredients of insulin detemir recombinant. It is often used in diabetes. (latest outcomes from Levemir 9,188 users)

On Aug, 24, 2016

3,097 people who take Novolog, Levemir are studied.


Number of reports submitted per year:

Novolog and Levemir drug interactions.

Drug effectiveness over time:

Novolog:
  • < 1 month: 33.0% - (1 of 3 people)
  • 1 - 6 months: 66.0% - (4 of 6 people)
  • 6 - 12 months: 100.0% - (1 of 1 people)
  • 1 - 2 years: 50.0% - (2 of 4 people)
  • 2 - 5 years: 66.0% - (6 of 9 people)
  • 5 - 10 years: 85.0% - (6 of 7 people)
  • 10+ years: 80.0% - (4 of 5 people)
  • not specified: 100.0% - (1 of 1 people)
Levemir:
  • < 1 month: 50.0% - (1 of 2 people)
  • 1 - 6 months: 50.0% - (4 of 8 people)
  • 6 - 12 months: 100.0% - (1 of 1 people)
  • 1 - 2 years: 42.0% - (3 of 7 people)
  • 2 - 5 years: 55.0% - (5 of 9 people)
  • 5 - 10 years: 100.0% - (4 of 4 people)
  • 10+ years: 75.0% - (3 of 4 people)
  • not specified: 0.0% - (0 of 1 people)

Drug effectiveness by gender:

Novolog:
  • female: 69.0% - (18 of 26 people)
  • male: 70.0% - (7 of 10 people)
Levemir:
  • female: 61.0% - (16 of 26 people)
  • male: 50.0% - (5 of 10 people)

Drug effectiveness by age:

Novolog:
  • 0-1: 0.0% - (0 of 0 people)
  • 2-9: 0.0% - (0 of 0 people)
  • 10-19: 100.0% - (1 of 1 people)
  • 20-29: 100.0% - (6 of 6 people)
  • 30-39: 100.0% - (2 of 2 people)
  • 40-49: 77.0% - (7 of 9 people)
  • 50-59: 46.0% - (7 of 15 people)
  • 60+: 66.0% - (2 of 3 people)
Levemir:
  • 0-1: 0.0% - (0 of 0 people)
  • 2-9: 0.0% - (0 of 0 people)
  • 10-19: 100.0% - (1 of 1 people)
  • 20-29: 100.0% - (6 of 6 people)
  • 30-39: 100.0% - (2 of 2 people)
  • 40-49: 55.0% - (5 of 9 people)
  • 50-59: 33.0% - (5 of 15 people)
  • 60+: 66.0% - (2 of 3 people)

Most common drug interactions over time *:

< 1 month:
  • intentional overdose
  • hypoglycaemia
  • acute stress disorder
  • hyperglycaemia
  • diabetes mellitus inadequate control
  • blood glucose increased
  • blood glucose decreased
  • fatigue
  • road traffic accident
  • cardiac failure congestive
1 - 6 months:
  • blood glucose increased
  • hypoglycaemia
  • hyperglycaemia
  • diabetes mellitus inadequate control
  • anti-insulin antibody increased
  • blood glucose fluctuation
  • anti-insulin antibody positive
  • acute stress disorder
  • intentional overdose
  • injection site erythema
6 - 12 months:
  • hypoglycaemia
  • diabetes mellitus inadequate control
  • blood glucose increased
  • jaundice neonatal
  • anti-insulin antibody positive
  • blood glucose fluctuation
  • dizziness
  • cerebral infarction
  • haemoglobin decreased
  • lipase increased
1 - 2 years:
  • dizziness
  • hypoglycaemia
  • nausea
  • sepsis
  • blood glucose increased
  • blood glucose fluctuation
  • diabetic gangrene
  • loss of consciousness
  • amnesia
  • bradycardia
2 - 5 years:
  • diabetes mellitus inadequate control
  • hypoglycaemia
  • anti-insulin antibody positive
  • hyperglycaemia
  • atrial fibrillation
  • blood glucose increased
  • drug eruption
  • malaise
  • oedema peripheral
  • drug exposure during pregnancy
5 - 10 years:
  • fall
  • pruritus
  • blood glucose increased
  • erythema
  • fatigue
  • injection site pain
  • swelling
  • bronchitis chronic
  • deafness transitory partial
  • death
10+ years:
  • concomitant disease progression
  • diabetic foot infection
  • anger
  • exhaustion, fatigue, lethargy, tiredness, weariness
  • gouty arthritis
  • hiccups
  • infection
  • inflammation
  • joint stiffness
  • lower blood pressure
not specified:
  • blood glucose increased
  • hypoglycaemia
  • nausea
  • blood glucose decreased
  • diabetes mellitus inadequate control
  • vomiting
  • dyspnoea
  • drug exposure during pregnancy
  • drug ineffective
  • pneumonia

Most common drug interactions by gender *:

female:
  • blood glucose increased
  • hypoglycaemia
  • blood glucose decreased
  • nausea
  • diabetes mellitus inadequate control
  • drug exposure during pregnancy
  • vomiting
  • fall
  • pancreatitis
  • dyspnoea
male:
  • blood glucose increased
  • hypoglycaemia
  • nausea
  • diabetes mellitus inadequate control
  • hyperglycaemia
  • vomiting
  • dyspnoea
  • diarrhoea
  • blood glucose decreased
  • pain

Most common drug interactions by age *:

0-1:
  • dermatitis diaper
  • feeding disorder neonatal
  • hypoglycaemia neonatal
  • jaundice neonatal
  • weight decrease neonatal
  • apgar score low
  • blood glucose decreased
  • dermatitis bullous
  • drug exposure during pregnancy
  • drug exposure via breast milk
2-9:
  • blood glucose increased
  • drug ineffective
  • idiopathic thrombocytopenic purpura
  • hypoglycaemia
  • blood glucose fluctuation
  • erythema multiforme
  • insomnia
  • loss of consciousness
  • rash
  • abdominal pain upper
10-19:
  • hypoglycaemia
  • petit mal epilepsy
  • hyperglycaemia
  • blood glucose increased
  • blood glucose fluctuation
  • hypoglycaemic seizure
  • anti-insulin antibody positive
  • blood glucose decreased
  • diabetic ketoacidosis
  • pruritus
20-29:
  • drug exposure during pregnancy
  • diabetic ketoacidosis
  • blood glucose increased
  • maculopathy
  • vitreous haemorrhage
  • diabetes mellitus inadequate control
  • anti-insulin antibody positive
  • hypoglycaemia
  • eczema
  • hypertension
30-39:
  • diabetic ketoacidosis
  • blood glucose increased
  • diplopia
  • drug exposure during pregnancy
  • gastroenteritis
  • pre-eclampsia
  • hypoglycaemia
  • pregnancy
  • drug ineffective
  • injection site pain
40-49:
  • blood glucose increased
  • pancreatitis
  • hypoglycaemia
  • nausea
  • weight increased
  • blood glucose decreased
  • blood glucose fluctuation
  • abdominal pain
  • convulsion
  • abortion spontaneous
50-59:
  • blood glucose increased
  • blood glucose decreased
  • nausea
  • diabetes mellitus inadequate control
  • hypoglycaemia
  • intentional overdose
  • acute stress disorder
  • dizziness
  • vomiting
  • weight decreased
60+:
  • blood glucose increased
  • hypoglycaemia
  • nausea
  • dyspnoea
  • diabetes mellitus inadequate control
  • vomiting
  • blood glucose decreased
  • fall
  • urticaria
  • hyperglycaemia

* Approximation only. Some reports may have incomplete information.

How to use the study: print a copy of the study and bring it to your health teams to ensure drug risks and benefits are fully discussed and understood.

Do you take Novolog and Levemir?

Can you answer these questions?

More questions for: Novolog, Levemir

You may be interested in these reviews

More reviews for: Novolog, Levemir

On eHealthMe, Novolog (insulin aspart recombinant) is often used to treat diabetes. Levemir (insulin detemir recombinant) is often used to treat diabetes. Find out below the conditions the drugs are used for and how effective they are.

What is the drug used for and how effecitve is it:


NOTE: The study is based on active ingredients and brand name. Other drugs that have the same active ingredients (e.g. generic drugs) are NOT considered.

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only, and has not been supported by scientific studies or clinical trials unless otherwise stated. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

You may report adverse side effects to the FDA at http://www.fda.gov/medwatch/ or 1-800-FDA-1088 (1-800-332-1088).

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.